MRI scans are strong diagnostics with high-definition images of what lies inside a body. Strong magnetic fields require precaution, as brought out by an instance where a young woman suffered very serious injuries due to an oversight in a metallic core within a silicone sex toy that she happened to have before the MRI scan. This makes a stark reminder about the potentially deadly consequences of missing metal objects when such procedures are being performed. In April 2023, a 23-year-old woman went into an MRI with a silicone plug containing a metal core that was not known.
She thought that the item is made entirely out of silicone according to the advertising. However, the strong magnetic field of the MRI machine interacted with the hidden metal, dragging the object through her body and causing excruciating pain. According to reports from the U.S. Food and Drug Administration (FDA), the scene was harrowing, with the woman screaming in agony and requiring immediate hospitalization. Despite pre-scan screenings, which are routine prior to a scan, the patient did not inform the facility that the object existed because he presumed it was purely non-metallic. This caused serious injuries that led to the patient's law suit against the manufacturer for deceitful misrepresentations of material content.
MRI machines employ magnets between 0.5 to 3 Tesla (T). This is thousands of times stronger than the Earth's magnetic field. The tremendous force causes ferromagnetic materials, like iron and nickel, to be magnetized quickly and become strongly attracted toward the magnet. Objects as small as hairpins or paper clips will accelerate at 40 miles per hour inside the magnetic field.
The force can lead to catastrophic injuries in items lodged within the body, such as metallic implants or foreign objects. Metallic cores within devices, like pacemakers or intrauterine devices, must be disclosed to radiologists to prevent such complications.
On these claims, Dr. Adam Taylor, a specialist in human anatomy, weighed his words in a international health website and added that the distance away and mass of this object would increase its velocity towards that of sound, "The acceleration would be phenomenal, but with a metallic core, it can't go anywhere near supersonic speeds. As for the size, the magnetic acceleration to the internal soft tissues would ensure that there could be severe intracranial trauma."
The injuries inflicted in this case likely involved damage to major blood vessels, nerves, or organs, highlighting the devastating impact of even minor oversight during an MRI scan.
This is not an isolated case. There are documented cases of metallic objects causing serious damage during MRI scans with a 65-year-old man with schizophrenia swallowed metal objects, including sockets and a hinge pin. The powerful magnetic field during an MRI scan caused the objects to rupture his stomach, resulting in serious injuries.
A toddler who ingested 11 small magnets perforated his bowel while undergoing a scan, making his case unique. In another deadly but extremely rare incident, there have been people who hide a firearm on themselves during MRI procedures. Magnetic attraction can trigger a discharge in a weapon and has led to some fatal injuries.
These cases emphasize the very strong need for adequate screening and patient education prior to an MRI.
Medical professionals have been trained to avoid risks. This is by properly screening a patient for metallic objects. In general, most pre-scan protocols include:
The case emphasizes the importance of product labeling by manufacturers, especially those products that are likely to unintentionally cause harm to health. The patient's assumption that her device was 100% silicone points to a larger problem in consumer markets with misinformation.
It also reminds the patients to report any possible dangers to the medical professionals, no matter how the objects look non-metallic. In sensitive cases, patients can request private discussions with healthcare providers to ensure safety without discomfort.
In the end, it is a joint effort from manufacturers, healthcare professionals, and patients that can prevent such tragedies. Manufacturers must ensure truthful marketing, while healthcare providers should educate patients about the dangers of metal objects in MRI settings. For patients, understanding the risks and actively participating in pre-scan disclosures can be lifesaving.
This young woman's experience is a sobering example of the unforeseen dangers posed by MRI machines when precautions are overlooked. It serves as a wake-up call to address gaps in patient awareness, medical protocols, and product transparency. By learning from this incident, the medical community and the public can work together to ensure MRI scans remain a safe and effective diagnostic tool.
Credit: AI Generated Image
The child death rate in the United States has increased significantly over the years. A new study published in the New England Journal of Medicine, showed that the child and adolescent death rate in the US rose to 6.6 percent between 2020 and 2023.
Caroline Raymond-King, an emergency medicine resident at Yale School of Medicine, and her colleagues analyzed data from three full years, from 2018 to 2023. The team found out the rates, trends, and massive issues behind this spike in deaths in the age bracket between 1 and 19 years old.
Even the lead researcher, Raymond-King herself, was inspired to work on this project because she witnessed the massive surge of injured children and adolescents in the emergency department.
The study has seen that the leading cause of death in the discussed age bracket is firearm incidents. Since 2020, it has remained the major reason for death among youth. In 2020 itself, the gun-related incidents surpassed motor vehicle crashes as the leading cause of death for children in the United States. Not only that, but the firearm-related incidents have also increased their share of the mortality rate of children. Between 2020 and 2023, child deaths due to firearms increased by 3.9 percent.
Along with the gun-related deaths, the other major issues, like motor vehicle crashes and drug poisoning deaths, have also seen an alarming upward trend. Between 2020 and 2023, the deaths related to road accidents rose by 8.6 percent. On the other hand, the mortality rate due to drug poisoning has gone up to 12.7 percent.
Other than those three major causes, there are other reasons behind these rising death rates, as follows: cancer, suffocation, congenital anomalies, drowning, heart disease, and fire.
Raymond-King's study has worked intensively on the ways to prevent these untimely deaths in children and adolescents. They have shared their views on the possible precautions to reduce risks.
Credit: AI generated image
Sexually transmitted infections (STIs) such as gonorrhea and syphilis have hit record levels in Europe in over a decade, according to new data from the European Centre for Disease Prevention and Control (ECDC).
As per the agency’s latest Annual Epidemiological Reports, there has been a sharp surge in bacterial STIs across Europe. It showed that the notifications of gonorrhea and syphilis, alongside congenital syphilis in 2024, reached their highest levels in over a decade, reflecting sustained transmission across multiple countries.
The ECDC blamed the "widening gaps in testing and prevention” behind the spike in STIs. It also called for urgent targeted action to prevent further spread, including among women of reproductive age.
The data for 2024 show that:
Bruno Ciancio, Head of Unit, Directly Transmitted and Vaccine-Preventable Diseases, said that left untreated, “these infections can cause severe complications, such as chronic pain and infertility and, in the case of syphilis, problems with the heart or nervous system”.
“Most distressingly, between 2023 and 2024, we have seen a near doubling of congenital syphilis, where infections pass directly to newborns, leading to potentially lifelong complications,” Ciancio added.
Transmission trends vary significantly across different population groups, the ECDC said.
Men who have sex with men remain the most disproportionately affected group, with the steepest long-term increases in gonorrhea and syphilis.
Among heterosexual populations, syphilis is rising, particularly among women of reproductive age, the consequences of which are a near doubling of congenital syphilis cases from 78 in 2023 to 140 in 2024 across 14 countries reporting data.
Reversing increasing trends in STI cases requires accessible prevention services, easier access to testing, faster treatment, and stronger partner notification to stop onward transmission.
The ECDC urged public health authorities to urgently update national STI strategies and strengthen surveillance systems to better monitor the impact of prevention efforts.
“Protecting your sexual health remains straightforward. Use condoms with new or multiple partners, and get tested if you have symptoms, such as pain, discharge, or an ulcer,” Ciancio said.
In the wake of increasing gonorrhea cases, the UK in 2025 rolled out a new vaccine. The vaccine, available at sexual health clinics across England, is being offered to people who are at the highest risk of getting gonorrhea.
This includes gay and bisexual men who have recently had multiple sexual partners and another bacterial STI within the last year. This new program is expected to protect thousands of people and save the NHS over £7.9 million in the next decade.
Gonorrhea is also increasing in the US, with the 2025 data from the Centers for Disease Control and Prevention showing that reported cases of gonorrhea, chlamydia, and syphilis have climbed by nearly 90 per cent since 2004. In 2023 alone, the country recorded more than 2.4 million cases of sexually transmitted infections.
The United States Food and Drug Administration (FDA) in December last year approved two new oral antibiotics to treat gonorrhea: Zoliflodacin and Gepotidacin. These approvals represent the first entirely new gonorrhea treatments in more than three decades.
Retatrutide has not yet received FDA approval. (Photo credit: AI generated)
Retatrutide, Eli Lilly’s new weight-loss drug, is in the final stages of its clinical trial, and the results seem very promising, the drugmaker said on Thursday. In a news release, they disclosed that the brand-new drug helped people lose up to 30 per cent of their body weight, which is about 85 pounds. The results are on a par with bariatric surgery, which helps people shed approximately 25 to 35 per cent of their total body weight within one to two years. Doctors say that this is the largest weight loss ever witnessed in a medical trial. While Lilly has not yet filed for approval from the Food and Drug Administration, the pharma giant says that it expects to file this year.
Retatrutide is similar to drugs like Zepbound and Wegovy that mimic the GLP-1 hormone. Retatrutide, however, along with GLP-1, mimics glucagon as well, thereby working like a triple agonist. This is unlike Zepbound, which is a double agonist. Researchers said that they have witnessed the impact of semaglutide and tirzepatide. However, Retatrutide's results went beyond the current weight-loss drugs on the market.
Dr Shauna Levy, medical director of the Tulane Weight Loss Center, explained that the current GLP-1s are not good enough to induce weight loss in people dealing with severe obesity and those who have a BMI of 35. Bariatric surgery can provide the same, but it seems that Retatrutide will be far more effective for people living with a high BMI who are trying to achieve a healthy weight.
Read more: Meet Retatrutide: The Unapproved Cousin Of Ozempic That Supports Weight Loss Differently
Retatrutide was in the third phase of its trials involving 2,300 obese or overweight participants. While the full results have not yet been released in a medical journal, participants who took the highest dose of the drug lost 28 per cent of their body weight, approximately 70 pounds. Furthermore, nearly half of the participants lost over 30 per cent of their body weight. The trial continued for 80 weeks, and a small group of severely obese patients took the drug for 104 weeks and lost about 85 pounds on average. Alternatively, patients who took high doses of Zepbound lost around 21 per cent of their body weight in 72 weeks. Wegovy users lost about 15 per cent of their weight in 68 weeks.
On the downside, there were some side effects too. Retatrutide users experienced the following side effects:
These have, however, been seen with GLP-1 drugs.
Retatrutide might be the next big weight-loss drug set to hit the market soon. It aims to maximise weight-loss results with fewer side effects for users. If approved, it could be helpful for patients who are struggling to lose weight on the current versions of GLP-1 drugs.
© 2024 Bennett, Coleman & Company Limited